Multimodal Treatment for Chronic Thromboembolic Pulmonary Hypertension: A Case Report

¹ Department of Pulmonary Vascular and General Medicine, Fuwai Yunnan Cardiovascular Hospital, Yunnan Provincial Cardiovascular Disease Clinical Medical Center/Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming 650000, Yunnan, China,

JCNR 2026 , 10(6), 41–46; https://doi.org/10.26689/jcnr.v10i6.15548

© 2026 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe disease characterized by pulmonary thromboembolism and vascular remodeling, the pathogenesis of which has not been fully elucidated. Currently, it is believed that the disease primarily originates from the shedding of thromboemboli from the right heart system, leading to mechanical obstruction of the pulmonary artery, which in turn triggers local inflammatory reactions, endothelial damage, and vascular remodeling. This results in elevated pulmonary artery pressure, ultimately leading to right heart failure. In recent years, a multimodal treatment strategy combining balloon pulmonary angioplasty (BPA) with targeted pharmacotherapy has demonstrated significant efficacy in the treatment of CTEPH. This article reports the diagnosis and treatment process of a 68-year-old female patient with CTEPH. After undergoing BPA combined with soluble guanylyl cyclase stimulators (riociguat), the patient’s clinical symptoms and hemodynamic parameters significantly improved.

References

Yang J, Madani M M, Mahmud E, et al., 2023, Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension. Chest, 164(2): 490–502.

Lang I M, 2008, Chronic Thromboembolic Pulmonary Hypertension. Dtsch Med Wochenschr, 133 Suppl 6: S206–S208.

Yang J Z, Poch D S, Ang L, et al., 2023, Balloon Pulmonary Angioplasty in the Current Era of CTEPH Treatment: How Did We Get Here? Pulmonary Circulation, 13(4): e12312.

Wilkens H, Konstantinides S, Lang I M, et al., 2018, Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. International Journal of Cardiology, 272S: 69–78.

Sharma M, Levine D J, 2021, Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Medicina (Kaunas), 57(4): 355.

van Kan C, Tramper J, Bresser P, et al., 2024, Patients with CTEPH and Mild Hemodynamic Severity of Disease Improve to a Similar Level of Exercise Capacity After Pulmonary Endarterectomy Compared to Patients with Severe Hemodynamic Disease. Pulmonary Circulation, 14(1): e12316.

Delcroix M, Pepke-Zaba J, D’Armini A M, et al., 2024, Worldwide CTEPH Registry: Long-Term Outcomes with Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy. Circulation, 150(17): 1354–1365.

Jaïs X, Brenot P, Bouvaist H, et al., 2022, Balloon Pulmonary Angioplasty Versus Riociguat for the Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension (RACE): A Multicentre, Phase 3, Open-Label, Randomised Controlled Trial and Ancillary Follow-Up. Lancet Respiratory Medicine, 10(10): 961–971.

Cottin V, Bensimon L, Raguideau F, et al., 2021, Hospital Costs of Balloon Pulmonary Angioplasty (BPA) Procedure and Management for CTEPH Patients: An Observational Study Based on the French National Hospital Discharge Database (PMSI). PLoS One, 16(12): e0260483.

Shimokawahara H, Nishizaki M, Inami T, et al., 2025, Effect of Riociguat on Exercise Following Balloon Pulmonary Angioplasty in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension in Japan (THERAPY-HYBRID-BPA): A Multicentre, Double-Blind, Randomised Study. Lancet Respiratory Medicine, 13(9): 789–799.

Previous article in this issue

Next article in this issue